电针治疗帕金森病失眠的有效性和安全性:多中心,随机,受控试验
Si-Chun Gu1, Ping Yin2, Min Yang3
1Department of Neurology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Movement disorders clinical practice
|May 28, 2025
概括
电针 (EA) 与假治疗相比,在帕金森病 (PD) 患者中显著改善了失眠. 这种非药物治疗方法为PD患者的睡眠障碍管理提供了安全有效的选择.
科学领域:
- 神经学 神经学
- 综合医学是一个整体的医学.
- 睡眠医学 睡眠医学
背景情况:
- 失眠是帕金森病 (PD) 的常见和严重的非运动症状,降低了患者的生活质量.
- 现有的PD相关失眠治疗方法在有效性,副作用和可访问性方面存在局限性.
- 电针 (EA) 是一种非药物治疗方法,对失眠有前途,但其在PD中的作用尚未研究.
研究的目的:
- 为了评估电针 (EA) 与假电针 (SA) 相比,用于治疗帕金森病 (PD) 患者的失眠的疗效和安全性.
主要方法:
- 一个多中心,参与者和评估者盲目的,随机的,假控制的试验与136名患有失眠的PD患者进行.
- 参与者接受EA或SA治疗8周,随后进行12周的随访期.
- 主要结局是第8周帕金森病睡眠量表 (PDSS) 评分的变化,次要结局包括主观睡眠指标和多睡眠学.
主要成果:
- 在EA和SA组中,PDSS得分显著改善,EA的效果更大 (13.50的差异).
- 二次结果,包括失眠严重程度指数,爱普沃思睡眠度量表和多睡眠图数据,在EA组中也显示出更大的改善.
- 在12周的随访期间,观察到的改善得到了持续,没有报告严重不良事件,并且成功失明得到证实.
结论:
- 电针 (EA) 是一种有效的治疗方法,可以改善帕金森病 (PD) 患者的失眠和相关睡眠障碍.
- 这项研究提供了I类证据,支持将EA纳入PD相关失眠的标准治疗方案.
- 在帕金森病中,EA为管理睡眠问题提供了一种安全而有前途的非药物治疗方案.
相关概念视频
02:07Blind Procedures
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...